1
|
Souilla L, Avesani M, Boisson A, Requirand A, Matecki S, Vincenti M, Werner O, De La Villeon G, Pommier V, Pasquie JL, Guillaumont S, Amedro P. Cardiorespiratory fitness, muscle fitness, and physical activity in children with long QT syndrome: A prospective controlled study. Front Cardiovasc Med 2023; 9:1081106. [PMID: 36712265 PMCID: PMC9874118 DOI: 10.3389/fcvm.2022.1081106] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2022] [Accepted: 12/28/2022] [Indexed: 01/13/2023] Open
Abstract
Background In children with congenital long QT syndrome (LQTS), the risk of arrhythmic events during exercise commonly makes it difficult to balance exercise restrictions versus promotion of physical activity. Nevertheless, in children with LQTS, cardiorespiratory fitness, muscle fitness, and physical activity, have been scarcely explored. Materials and methods In this prospective, controlled, cross-sectional study, 20 children with LQTS (12.7 ± 3.7 years old) and 20 healthy controls (11.9 ± 2.4 years old) were enrolled. All participants underwent a cardiopulmonary exercise test, a muscular architecture ultrasound assessment, (cross-sectional area on right rectus femoris and pennation angle), a handgrip muscular strength evaluation, and a standing long broad jump test. The level of physical activity was determined using with a waist-worn tri-axial accelerometer (Actigraph GT3X). Results Peak oxygen uptake (VO2peak) and ventilatory anaerobic threshold (VAT) were lower in children with LQTS than in healthy controls (33.9 ± 6.2 mL/Kg/min vs. 40.1 ± 6.6 mL/Kg/min, P = 0.010; 23.8 ± 5.1 mL/Kg/min vs. 28.8 ± 5.5 mL/Kg/min, P = 0.007, respectively). Children with LQTS had lower standing long broad jump distance (119.5 ± 33.2 cm vs. 147.3 ± 36.1 cm, P = 0.02) and pennation angle (12.2 ± 2.4° vs. 14.3 ± 2.8°, P = 0.02). No differences in terms of moderate-to-vigorous physical activity were observed (36.9 ± 12.9 min/day vs. 41.5 ± 18.7 min/day, P = 0.66), but nearly all children were below the WHO guidelines. Conclusion Despite similar physical activity level, cardiorespiratory fitness and muscle fitness in children with LQTS were lower than in healthy controls. The origin of this limitation seemed to be multifactorial, involving beta-blocker induced chronotropic limitation, physical and muscle deconditioning. Cardiovascular rehabilitation could be of interest in children with LQTS with significant physical limitation.
Collapse
Affiliation(s)
- Luc Souilla
- Department of Paediatric and Congenital Cardiology, M3C Regional Reference Centre, University Hospital, Montpellier, France,PhyMedExp, Univ Montpellier, INSERM, French National Centre for Scientific Research (CNRS), Montpellier, France
| | - Martina Avesani
- Department of Paediatric and Adult Congenital Cardiology, M3C National Reference Centre, Bordeaux University Hospital, Pessac, France
| | - Aymeric Boisson
- Department of Paediatric and Congenital Cardiology, M3C Regional Reference Centre, University Hospital, Montpellier, France
| | - Anne Requirand
- Department of Paediatric and Congenital Cardiology, M3C Regional Reference Centre, University Hospital, Montpellier, France,Department of Physiology, University Hospital of Montpellier, Montpellier, France
| | - Stefan Matecki
- PhyMedExp, Univ Montpellier, INSERM, French National Centre for Scientific Research (CNRS), Montpellier, France,Department of Physiology, University Hospital of Montpellier, Montpellier, France
| | - Marie Vincenti
- Department of Paediatric and Congenital Cardiology, M3C Regional Reference Centre, University Hospital, Montpellier, France,PhyMedExp, Univ Montpellier, INSERM, French National Centre for Scientific Research (CNRS), Montpellier, France
| | - Oscar Werner
- Department of Paediatric and Congenital Cardiology, M3C Regional Reference Centre, University Hospital, Montpellier, France,Paediatric Cardiology and Rehabilitation Unit, Saint-Pierre Institute, Palavas-Les-Flots, France
| | - Gregoire De La Villeon
- Department of Paediatric and Congenital Cardiology, M3C Regional Reference Centre, University Hospital, Montpellier, France,Paediatric Cardiology and Rehabilitation Unit, Saint-Pierre Institute, Palavas-Les-Flots, France
| | - Victor Pommier
- Department of Paediatric and Congenital Cardiology, M3C Regional Reference Centre, University Hospital, Montpellier, France,Paediatric Cardiology and Rehabilitation Unit, Saint-Pierre Institute, Palavas-Les-Flots, France
| | - Jean-Luc Pasquie
- Department of Paediatric and Congenital Cardiology, M3C Regional Reference Centre, University Hospital, Montpellier, France,PhyMedExp, Univ Montpellier, INSERM, French National Centre for Scientific Research (CNRS), Montpellier, France
| | - Sophie Guillaumont
- Department of Paediatric and Congenital Cardiology, M3C Regional Reference Centre, University Hospital, Montpellier, France,Paediatric Cardiology and Rehabilitation Unit, Saint-Pierre Institute, Palavas-Les-Flots, France
| | - Pascal Amedro
- Department of Paediatric and Adult Congenital Cardiology, M3C National Reference Centre, Bordeaux University Hospital, Pessac, France,Inserm, U1045, Institut Hospitalo-Universitaire (IHU) Liryc, Bordeaux Cardio-Thoracic Research Centre, Electrophysiology and Heart Modelling Institute, University of Bordeaux, Pessac, France,*Correspondence: Pascal Amedro,
| |
Collapse
|
2
|
Yernaux M, Chretien S, Rothé F, Wang X, Rouas G, Boisson A, Kotecki N, Mailliez A, Larsimont D, Venet D, Sotiriou C, Buisseret L. 224P Immune characterization of de novo metastatic breast cancer. Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100335] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
3
|
Boisson A, Vincenti M, Guillaumont S. Fetal screening and prevention of autoimmune heart block: What about the French cardiofetalist practice? Archives of Cardiovascular Diseases Supplements 2022. [DOI: 10.1016/j.acvdsp.2022.07.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
4
|
Boisson A, De La Villeon G, Huguet H, Abassi H, Pasquie JL, Lavastre K, Matecki S, Guillaumont S, Requirand A, Calderon J, Amedro P. Physical activity and aerobic fitness in children with inherited cardiac diseases. Arch Cardiovasc Dis 2021; 114:727-736. [PMID: 34756533 DOI: 10.1016/j.acvd.2021.07.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/04/2021] [Revised: 07/01/2021] [Accepted: 07/27/2021] [Indexed: 10/20/2022]
Abstract
BACKGROUND Because of sports and exercise restrictions, children with inherited cardiac disease are at risk of physical deconditioning. Guidelines on sports participation in cardiovascular disease have become less restrictive over time, but their real-life application and behavioural impact have seldom been evaluated in children. AIMS We aimed to evaluate adherence to the 2020 European Society of Cardiology guidelines on sports and exercise in children with inherited cardiac arrhythmia and inherited cardiomyopathy; we also sought to evaluate their aerobic fitness, and the behavioural impact of inherited cardiac diseases on physical activity in children. METHODS Children aged 6-18 years with inherited cardiomyopathy or inherited cardiac arrhythmia were eligible for this cross-sectional study. Clinical, demographic and qualitative data were analysed. RESULTS A total of 32 children were included in the study (mean age 12.7±3.5 years). Most children (81.3%) complied with the 2020 European Society of Cardiology guidelines; they were physically active and had good overall aerobic fitness, with a mean peak oxygen uptake (VO2) value of 36.5±8.0mL/kg/min (84.0±17.2% of theoretical value). As a result of personal or parental behaviour, some children at risk of sudden cardiac death did not comply with the recommended upper limit of physical activity intensity, whereas others at low risk did not comply with the lower limit. CONCLUSION Most children with inherited cardiac arrhythmia or inherited cardiomyopathy complied with current 2020 European Society of Cardiology guidelines on sports cardiology and exercise in cardiovascular disease.
Collapse
Affiliation(s)
- Aymeric Boisson
- Paediatric and Congenital Cardiology Department, M3C Regional Reference Centre, University Hospital, 34295 Montpellier, France
| | - Gregoire De La Villeon
- Paediatric and Congenital Cardiology Department, M3C Regional Reference Centre, University Hospital, 34295 Montpellier, France; Paediatric Cardiology and Rehabilitation Unit, Saint-Pierre Institute, 34250 Palavas-Les-Flots, France
| | - Helena Huguet
- Clinical Research and Epidemiology Unit, CHU de Montpellier, University of Montpellier, 34295 Montpellier, France
| | - Hamouda Abassi
- Paediatric and Congenital Cardiology Department, M3C Regional Reference Centre, University Hospital, 34295 Montpellier, France; Inserm, PhyMedExp, CNRS, University of Montpellier, 34295 Montpellier, France
| | - Jean-Luc Pasquie
- Paediatric and Congenital Cardiology Department, M3C Regional Reference Centre, University Hospital, 34295 Montpellier, France; Inserm, PhyMedExp, CNRS, University of Montpellier, 34295 Montpellier, France
| | - Kathleen Lavastre
- Paediatric and Congenital Cardiology Department, M3C Regional Reference Centre, University Hospital, 34295 Montpellier, France
| | - Stefan Matecki
- Inserm, PhyMedExp, CNRS, University of Montpellier, 34295 Montpellier, France; Department of Physiology, CHU de Montpellier, 34295 Montpellier, France
| | - Sophie Guillaumont
- Paediatric and Congenital Cardiology Department, M3C Regional Reference Centre, University Hospital, 34295 Montpellier, France; Paediatric Cardiology and Rehabilitation Unit, Saint-Pierre Institute, 34250 Palavas-Les-Flots, France
| | - Anne Requirand
- Paediatric and Congenital Cardiology Department, M3C Regional Reference Centre, University Hospital, 34295 Montpellier, France
| | - Johanna Calderon
- Paediatric and Congenital Cardiology Department, M3C Regional Reference Centre, University Hospital, 34295 Montpellier, France; Inserm, PhyMedExp, CNRS, University of Montpellier, 34295 Montpellier, France
| | - Pascal Amedro
- Department of Paediatric and Adult Congenital Cardiology, M3C National Reference Centre, Bordeaux University Hospital, 33604 Pessac, France; Inserm, U1045, IHU Liryc, Bordeaux Cardio-Thoracic Research Centre, Electrophysiology and Heart Modelling Institute, University of Bordeaux, Fondation Bordeaux Université, 33604 Pessac, France.
| |
Collapse
|
5
|
Amedro P, Werner O, Abassi H, Boisson A, Souilla L, Guillaumont S, Calderon J, Requirand A, Vincenti M, Pommier V, Matecki S, De La Villeon G, Lavastre K, Lacampagne A, Picot MC, Beyler C, Delclaux C, Dulac Y, Guitarte A, Charron P, Denjoy-Urbain I, Probst V, Baruteau AE, Chevalier P, Di Filippo S, Thambo JB, Bonnet D, Pasquie JL. Health-related quality of life and physical activity in children with inherited cardiac arrhythmia or inherited cardiomyopathy: the prospective multicentre controlled QUALIMYORYTHM study rationale, design and methods. Health Qual Life Outcomes 2021; 19:187. [PMID: 34321045 PMCID: PMC8317438 DOI: 10.1186/s12955-021-01825-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2021] [Accepted: 07/18/2021] [Indexed: 02/07/2023] Open
Abstract
Background Advances in paediatric cardiology have improved the prognosis of children with inherited cardiac disorders. However, health-related quality of life (QoL) and physical activity have been scarcely analysed in children with inherited cardiac arrhythmia or inherited cardiomyopathy. Moreover, current guidelines on the eligibility of young athletes with inherited cardiac disorders for sports participation mainly rely on expert opinions and remain controversial. Methods The QUALIMYORYTHM trial is a multicentre observational controlled study. The main objective is to compare the QoL of children aged 6 to 17 years old with inherited cardiac arrhythmia (long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, or arrhythmogenic right ventricular dysplasia), or inherited cardiomyopathy (hypertrophic, dilated, or restrictive cardiomyopathy), to that of age and gender-matched healthy subjects. The secondary objective is to assess their QoL according to the disease’s clinical and genetic characteristics, the level of physical activity and motivation for sports, the exercise capacity, and the socio-demographic data. Participants will wear a fitness tracker (ActiGraph GT3X accelerometer) for 2 weeks. A total of 214 children are required to observe a significant difference of 7 ± 15 points in the PedsQL, with a power of 90% and an alpha risk of 5%. Discussion After focusing on the survival in children with inherited cardiac disorders, current research is expanding to patient-reported outcomes and secondary prevention. The QUALIMYORYTHM trial intends to improve the level of evidence for future guidelines on sports eligibility in this population. Trial registration ClinicalTrials.gov Identifier: NCT04712136, registered on January 15th, 2021 (https://clinicaltrials.gov/ct2/show/NCT04712136).
Collapse
Affiliation(s)
- Pascal Amedro
- Department of Paediatric and Adult Congenital Cardiology, M3C National Reference Centre, Haut-Lévêque Cardiology Hospital, Bordeaux University Hospital, Avenue de Magellan, 33604, Pessac Cedex, France. .,INSERM, Bordeaux Cardio-Thoracic Research Centre, U1045, University of Bordeaux, Pessac, France. .,IHU Liryc, Electrophysiology and Heart Modelling Institute, Fondation Bordeaux Université, Pessac, France.
| | - Oscar Werner
- Paediatric and Congenital Cardiology Department, M3C Regional Reference CHD Centre, Montpellier University Hospital, Montpellier, France
| | - Hamouda Abassi
- Paediatric and Congenital Cardiology Department, M3C Regional Reference CHD Centre, Montpellier University Hospital, Montpellier, France.,PhyMedExp, INSERM, CNRS, University of Montpellier, Montpellier, France
| | - Aymeric Boisson
- Paediatric and Congenital Cardiology Department, M3C Regional Reference CHD Centre, Montpellier University Hospital, Montpellier, France
| | - Luc Souilla
- Paediatric and Congenital Cardiology Department, M3C Regional Reference CHD Centre, Montpellier University Hospital, Montpellier, France
| | - Sophie Guillaumont
- Paediatric and Congenital Cardiology Department, M3C Regional Reference CHD Centre, Montpellier University Hospital, Montpellier, France.,Paediatric Cardiology and Rehabilitation Unit, Institut-Saint-Pierre, Palavas-Les-Flots, France
| | - Johanna Calderon
- Paediatric and Congenital Cardiology Department, M3C Regional Reference CHD Centre, Montpellier University Hospital, Montpellier, France.,PhyMedExp, INSERM, CNRS, University of Montpellier, Montpellier, France
| | - Anne Requirand
- Paediatric and Congenital Cardiology Department, M3C Regional Reference CHD Centre, Montpellier University Hospital, Montpellier, France
| | - Marie Vincenti
- Paediatric and Congenital Cardiology Department, M3C Regional Reference CHD Centre, Montpellier University Hospital, Montpellier, France.,PhyMedExp, INSERM, CNRS, University of Montpellier, Montpellier, France
| | - Victor Pommier
- Paediatric and Congenital Cardiology Department, M3C Regional Reference CHD Centre, Montpellier University Hospital, Montpellier, France.,Paediatric Cardiology and Rehabilitation Unit, Institut-Saint-Pierre, Palavas-Les-Flots, France
| | - Stefan Matecki
- Paediatric and Congenital Cardiology Department, M3C Regional Reference CHD Centre, Montpellier University Hospital, Montpellier, France.,PhyMedExp, INSERM, CNRS, University of Montpellier, Montpellier, France
| | - Gregoire De La Villeon
- Paediatric and Congenital Cardiology Department, M3C Regional Reference CHD Centre, Montpellier University Hospital, Montpellier, France.,Paediatric Cardiology and Rehabilitation Unit, Institut-Saint-Pierre, Palavas-Les-Flots, France
| | - Kathleen Lavastre
- Paediatric and Congenital Cardiology Department, M3C Regional Reference CHD Centre, Montpellier University Hospital, Montpellier, France
| | - Alain Lacampagne
- PhyMedExp, INSERM, CNRS, University of Montpellier, Montpellier, France
| | - Marie-Christine Picot
- Epidemiology and Clinical Research Department, Montpellier University Hospital, Montpellier, France
| | - Constance Beyler
- Paediatric Cardiology and Physiology Department, Robert Debré University Hospital, University of Paris, AP-HP, Paris, France
| | - Christophe Delclaux
- Paediatric Cardiology and Physiology Department, Robert Debré University Hospital, University of Paris, AP-HP, Paris, France
| | - Yves Dulac
- Paediatric Cardiology Department, M3C Regional Reference Centre, Toulouse University Hospital, Toulouse, France
| | - Aitor Guitarte
- Paediatric Cardiology Department, M3C Regional Reference Centre, Toulouse University Hospital, Toulouse, France
| | - Philippe Charron
- Department of Cardiology, National Reference Centre for Inherited Cardiomyopathy, University of Paris, AP-HP, Paris, France
| | - Isabelle Denjoy-Urbain
- Department of Cardiology, National Reference Centre for Inherited Cardiomyopathy, University of Paris, AP-HP, Paris, France
| | - Vincent Probst
- Department of Cardiology, National Reference Centre for Inherited Cardiac Arrhythmia, L'institut du thorax, INSERM, CNRS, University of Nantes, Nantes University Hospital, Nantes, France
| | - Alban-Elouen Baruteau
- Department of Pediatric Cardiology and Pediatric Cardiac Surgery, L'Institut du Thorax, INSERM, CNRS, University of Nantes, Nantes University Hospital, Nantes, France
| | - Philippe Chevalier
- Department of Congenital Cardiology, National Reference Centre for Inherited Cardiac Arrhythmia, University of Lyon, Lyon University Hospital, Lyon, France
| | - Sylvie Di Filippo
- Department of Congenital Cardiology, National Reference Centre for Inherited Cardiac Arrhythmia, University of Lyon, Lyon University Hospital, Lyon, France
| | - Jean-Benoit Thambo
- Department of Paediatric and Adult Congenital Cardiology, M3C National Reference Centre, Haut-Lévêque Cardiology Hospital, Bordeaux University Hospital, Avenue de Magellan, 33604, Pessac Cedex, France.,INSERM, Bordeaux Cardio-Thoracic Research Centre, U1045, University of Bordeaux, Pessac, France.,IHU Liryc, Electrophysiology and Heart Modelling Institute, Fondation Bordeaux Université, Pessac, France
| | - Damien Bonnet
- Paediatric Cardiology Department, Necker-Enfants malades, M3C National Reference Centre, University of Paris, AP-HP, Paris, France
| | - Jean-Luc Pasquie
- Cardiology Department of Cardiology, Regional Reference Centre for Inherited Cardiac Arrhythmia, Montpellier University Hospital, Montpellier, France.,PhyMedExp, INSERM, CNRS, University of Montpellier, Montpellier, France
| |
Collapse
|
6
|
Pabois A, Bodo V, Boisson A, Crosignani S, De Henau O, Detheux M, Garaud S, Lager J, Martinoli C, Mercier M, Naveaux C, Thomas N, Wald N, Vezzu A, Willard-Gallo K, Houthuys E. Multiplex IHC panel development for adenosine pathway markers and TIL in human cancer specimens. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz452.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
7
|
De Silva P, Stamatopoulos B, Chi V, Garaud S, Francois R, Thibaud V, Solinas C, Boisson A, Duvillier H, Rouas R, Lewalle P, Gallo K, Bron D. BACH2 AND FOXP1 GENE EXPRESSIONS ARE SIGNIFICANTLY ALTERED IN T AND B CELLS FROM CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS COMPARED TO AGED-MATCHED HEALTHY DONORS IMPACTING SURVIVAL. J Geriatr Oncol 2019. [DOI: 10.1016/s1879-4068(19)31173-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
8
|
De Silva P, Stamatopoulos B, Dang Chi V, Garaud S, Francois R, Thibaud V, Solinas C, Boisson A, Duvillier H, Rouas R, Lewalle P, Willard-Gallo K, Bron D. FOXP1, PD-1 AND PD-L1 ARE SIGNIFICANTLY UPREGULATED IN LYMPHOCYTES FROM CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS COMPARED TO AGE-MATCHED HEALTHY DONORS. Hematol Oncol 2019. [DOI: 10.1002/hon.46_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- P. De Silva
- Hematology; Institut Jules Bordet, ULB; Brussels Belgium
| | | | - V. Dang Chi
- Hematology; Institut Jules Bordet, ULB; Brussels Belgium
| | - S. Garaud
- Molecular Immunology Unit; Institut Jules Bordet, ULB; Brussels Belgium
| | - R. Francois
- Breast Cancer Translational Research Laboratory; Institut Jules Bordet, ULB; Brussels Belgium
| | - V. Thibaud
- Hematology; Institut Jules Bordet, ULB; Brussels Belgium
| | - C. Solinas
- Molecular Immunology Unit; Institut Jules Bordet, ULB; Brussels Belgium
| | - A. Boisson
- Molecular Immunology Unit; Institut Jules Bordet, ULB; Brussels Belgium
| | - H. Duvillier
- Flow Cytometry Core Facility; Institut Jules Bordet, ULB; Brussels Belgium
| | - R. Rouas
- Hematology; Institut Jules Bordet, ULB; Brussels Belgium
| | - P. Lewalle
- Hematology; Institut Jules Bordet, ULB; Brussels Belgium
| | - K. Willard-Gallo
- Molecular Immunology Unit; Institut Jules Bordet, ULB; Brussels Belgium
| | - D. Bron
- Hematology; Institut Jules Bordet, ULB; Brussels Belgium
| |
Collapse
|
9
|
Langouo Fontsa M, Noel G, Garaud S, de Wind A, Van den Eynden G, Boisson A, Naveaux C, Larsimont D, Piccart M, Willard-Gallo K. Immune functions of follicular helper CD4+CXCR5+ T cells in human breast cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz099.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
10
|
Fontaine C, Van den Eynden G, de Wind R, Boisson A, Renard V, Van den Bulck H, Vuylsteke P, Glorieux P, Dopchie C, Decoster L, De Grève J, Awada A, Wildiers H, Willard-Gallo K. Abstract P2-08-47: Evaluation of stromal tumor-infiltrating lymphocytes (sTIL) and tertiary lymphoid structures (TLS) in early breast cancer patients with triple negative breast cancer(TNBC) included in a prospective study of neoadjuvant chemotherapy (NAC) with Epirubicin and cyclophosphamide (EC) and carboplatin-paclitaxel (PC) (BSMO 2014-01). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-08-47] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: BSMO 2014-01 is a completed prospective phase 2 study evaluating the efficacy of neoadjuvant EC and PC. One of the secondary endpoints was the correlation of sTIL with response, pCR and survival. We also assessed the relationship between sTIL and TLS in the diagnostic biopsies.
Methods: Stromal TIL (sTIL) were evaluated on H&E stained tumor biopsies before the start of the NAC according to the criteria described by Salgado et al(1). Scores were defined as "low" or "high" if lymphocytic infiltration in the stroma around the tumor was ≤ 10% or > 10%. TLS are ectopic lymph node-like structures recently identified in breast cancer. TLS were counted using a dual IHC stain for CD3 (T cells) and CD20 (B cells) and categorized as "little" if the TLS occupied < 10% or "moderate to abundant" if they occupied ≥ 10% of the adjacent tissue. The correlation between sTIL and pathologic parameters was analyzed using the chi-square test; DFS and OS between the groups was estimated by using the log-rank test.
Results: So far we could quantify the number of sTIL in 38 out of 63 TNBC pts treated with neoadjuvant EC-PC. Twenty eight pts had a high sTIL score and 10 pts had a low sTIL score. The high-sTIL group (19/28) achieved a numerical higher pathologic complete remission (pCR) rate than the low-sTIL group (5/10) (p=0.3); both groups had a comparable disease free survival of 28.6 mths and 26.7 mths respectively (p=0.7). The overall survival was similar:29 mths and 27.8 mths respectively (p=0.8). Stromal TLS were identified in 10 out 23 samples available for this analysis and we could demonstrate a positive correlation between high levels of sTIL and high levels of moderate to abundant TLS(CD3) in the adjacent tissue in six out of the ten samples in which TLS were present (p=0.1).
Conclusion: These preliminary results could not confirm the results published by Denkert et al earlier this year(2). A trend for correlation of the presence of high sTIL with moderate to abundant levels of TLS was found. Analysis on the remaining samples of all patients included in the study and correlation with outcome is ongoing and these completed results will be presented.
(1)Assessing Tumor-infiltrating lymphocytes in solid tumors. Hendry S, Salgado R et al. Adv Anat Pathol 2017; 235-251.
(2)Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer. Denkert C et al. Lancet Oncol 2018; 40-50.
Citation Format: Fontaine C, Van den Eynden G, de Wind R, Boisson A, Renard V, Van den Bulck H, Vuylsteke P, Glorieux P, Dopchie C, Decoster L, De Grève J, Awada A, Wildiers H, Willard-Gallo K. Evaluation of stromal tumor-infiltrating lymphocytes (sTIL) and tertiary lymphoid structures (TLS) in early breast cancer patients with triple negative breast cancer(TNBC) included in a prospective study of neoadjuvant chemotherapy (NAC) with Epirubicin and cyclophosphamide (EC) and carboplatin-paclitaxel (PC) (BSMO 2014-01) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-08-47.
Collapse
Affiliation(s)
- C Fontaine
- UZ Brussel, Jette, Belgium; Institut Jules Bordet, Brussels, Belgium; UZ Leuven, Leuven, Belgium; BSMO, Brussels, Belgium
| | - G Van den Eynden
- UZ Brussel, Jette, Belgium; Institut Jules Bordet, Brussels, Belgium; UZ Leuven, Leuven, Belgium; BSMO, Brussels, Belgium
| | - R de Wind
- UZ Brussel, Jette, Belgium; Institut Jules Bordet, Brussels, Belgium; UZ Leuven, Leuven, Belgium; BSMO, Brussels, Belgium
| | - A Boisson
- UZ Brussel, Jette, Belgium; Institut Jules Bordet, Brussels, Belgium; UZ Leuven, Leuven, Belgium; BSMO, Brussels, Belgium
| | - V Renard
- UZ Brussel, Jette, Belgium; Institut Jules Bordet, Brussels, Belgium; UZ Leuven, Leuven, Belgium; BSMO, Brussels, Belgium
| | - H Van den Bulck
- UZ Brussel, Jette, Belgium; Institut Jules Bordet, Brussels, Belgium; UZ Leuven, Leuven, Belgium; BSMO, Brussels, Belgium
| | - P Vuylsteke
- UZ Brussel, Jette, Belgium; Institut Jules Bordet, Brussels, Belgium; UZ Leuven, Leuven, Belgium; BSMO, Brussels, Belgium
| | - P Glorieux
- UZ Brussel, Jette, Belgium; Institut Jules Bordet, Brussels, Belgium; UZ Leuven, Leuven, Belgium; BSMO, Brussels, Belgium
| | - C Dopchie
- UZ Brussel, Jette, Belgium; Institut Jules Bordet, Brussels, Belgium; UZ Leuven, Leuven, Belgium; BSMO, Brussels, Belgium
| | - L Decoster
- UZ Brussel, Jette, Belgium; Institut Jules Bordet, Brussels, Belgium; UZ Leuven, Leuven, Belgium; BSMO, Brussels, Belgium
| | - J De Grève
- UZ Brussel, Jette, Belgium; Institut Jules Bordet, Brussels, Belgium; UZ Leuven, Leuven, Belgium; BSMO, Brussels, Belgium
| | - A Awada
- UZ Brussel, Jette, Belgium; Institut Jules Bordet, Brussels, Belgium; UZ Leuven, Leuven, Belgium; BSMO, Brussels, Belgium
| | - H Wildiers
- UZ Brussel, Jette, Belgium; Institut Jules Bordet, Brussels, Belgium; UZ Leuven, Leuven, Belgium; BSMO, Brussels, Belgium
| | - K Willard-Gallo
- UZ Brussel, Jette, Belgium; Institut Jules Bordet, Brussels, Belgium; UZ Leuven, Leuven, Belgium; BSMO, Brussels, Belgium
| |
Collapse
|
11
|
Solinas C, de Wind A, Van den Eynden G, Ameye L, Garaud S, De Silva P, Boisson A, Noel G, Langouo Fontsa M, Buisseret L, de Azambuja E, Francis PA, Di Leo A, Crown JP, Sotiriou C, Larsimont D, Paesmans M, Piccart-Gebhart M, Willard-Gallo K. Abstract PD5-09: Immune parameters associated with survival in triple negative and HER2-positive breast cancer patients with 10 years of follow-up. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-pd5-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The clinical utility of tumor-infiltrating lymphocytes (TIL) is actively being investigated in breast cancer (BC). It is unclear whether TIL spatial location and organization in tertiary lymphoid structures (TLS) have an impact on prognosis. Additionally, the significance of PD-1 and PD-L1 expression is being debated due to conflicting data from several studies. We hypothesize that the presence, extent and spatial location of multiple immune biomarkers, reflecting ongoing immune responses, will be consistently associated with a good prognosis in highly infiltrated BC [triple-negative (TNBC) and HER2+].
The relationship between these immune biomarkers and clinical outcome was examined in the TNBC and HER2+ cohorts of node-positive BC patients enrolled in the BIG 02-98 adjuvant phase III trial with available material for immunohistochemical (IHC) labeling (N=113 and N=136, respectively). HER2+ patients did not receive trastuzumab. Dual IHC staining was performed on full-face consecutive tissue sections. Scoring was independently performed by two pathologists, blinded to the clinical data, and included: global, intratumoral and stromal TIL and TLS, assessed on CD3/CD20 slides; the percentage and location of PD-1 and PD-L1 expression, assessed on PD-1/PD-L1 slides. TIL were considered as a categorical variable with different cut-offs used for each parameter and for each cohort (TNBC and HER2+). Invasive disease-free survival (I-DFS) and overall survival (OS) were analyzed (median follow-up: 10 years). Cox proportional hazard models were used for survival analyses.
The TNBC cohort revealed an association between global TIL and outcome [adjusted hazard ratio (HR) for I-DFS: 0.27 (0.15-0.51); OS: 0.26 (0.13-0.53)]. Similar results were observed for stromal and intratumoral TIL. PD-L1 expression within TLS was an independent predictor of OS, after adjustment for tumor size and age [HR: 0.30 (0.09-0.99)]. Multivariate analysis reveals this effect was principally driven by high stromal TIL (>17.5% based on CD3/CD20 assessment) (χ2 OS: p=0.009). In contrast, no significant prognostic associations were found in the overall HER2+ cohort. However high T cell TIL were associated with improved I-DFS and OS in the ER-/HER2+ group [I-DFS: 0.34 (0.14-0.80); OS: 0.32 (0.12-0.86)] and stromal TIL were associated with improved I-DFS in the ER+/HER2+ group [HR: 0.29 (0.09-0.94)] (univariate analyses). No significant associations between the number of TLS nor the expression of PD-1 with outcomes were observed in either cohorts.
The presence of PD-L1+ TLS, driven by high baseline TIL, was associated with an excellent prognosis in node-positive TNBC. This observation might reflect specific immune activities taking place in these mini lymph node-like structures adjacent to the tumor bed where specific antitumor memory immune responses could be generated. No different prognostic impact was observed when analyzing TIL spatial location. Although the statistical power of the study might be limited, in line with previous findings our data reveal that, among the immune parameters evaluated, TIL are the strongest predictor of outcome in TNBC, while PD-L1+ TLS could be a new and important parameter that requires further investigation.
Citation Format: Solinas C, de Wind A, Van den Eynden G, Ameye L, Garaud S, De Silva P, Boisson A, Noel G, Langouo Fontsa M, Buisseret L, de Azambuja E, Francis PA, Di Leo A, Crown JP, Sotiriou C, Larsimont D, Paesmans M, Piccart-Gebhart M, Willard-Gallo K. Immune parameters associated with survival in triple negative and HER2-positive breast cancer patients with 10 years of follow-up [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD5-09.
Collapse
Affiliation(s)
- C Solinas
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - A de Wind
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - G Van den Eynden
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - L Ameye
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - S Garaud
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - P De Silva
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - A Boisson
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - G Noel
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - M Langouo Fontsa
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - L Buisseret
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - E de Azambuja
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - PA Francis
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - A Di Leo
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - JP Crown
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - C Sotiriou
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - D Larsimont
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - M Paesmans
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - M Piccart-Gebhart
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| | - K Willard-Gallo
- Molecular Immunology Unit, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Bruxelles, Belgium; Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Melbourne, Australia; Hospital of Prato, Prato, Italy; Medical Oncology, Vincent's University Hospital, Dublin, Ireland
| |
Collapse
|
12
|
Solinas C, Richard F, Garaud S, De Silva P, de Wind A, Van Den Eyden G, Gu-Trantien C, Langouo Fontsa M, Noël G, Boisson A, Naveaux C, Duvillier H, Craciun L, Larsimont D, Willard-Gallo K. Unsupervised analysis of the extent, organization and phenotype of tumor-infiltrating lymphocytes in breast cancer identifies two major clusters. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy493.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
13
|
Guihéneuf N, Bour O, Boisson A, Le Borgne T, Becker MW, Nigon B, Wajiduddin M, Ahmed S, Maréchal JC. Insights about transport mechanisms and fracture flow channeling from multi-scale observations of tracer dispersion in shallow fractured crystalline rock. J Contam Hydrol 2017; 206:18-33. [PMID: 28965710 DOI: 10.1016/j.jconhyd.2017.09.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/24/2017] [Revised: 09/06/2017] [Accepted: 09/11/2017] [Indexed: 06/07/2023]
Abstract
In fractured media, solute transport is controlled by advection in open and connected fractures and by matrix diffusion that may be enhanced by chemical weathering of the fracture walls. These phenomena may lead to non-Fickian dispersion characterized by early tracer arrival time, late-time tailing on the breakthrough curves and potential scale effect on transport processes. Here we investigate the scale dependency of these processes by analyzing a series of convergent and push-pull tracer experiments with distance of investigation ranging from 4m to 41m in shallow fractured granite. The small and intermediate distances convergent experiments display a non-Fickian tailing, characterized by a -2 power law slope. However, the largest distance experiment does not display a clear power law behavior and indicates possibly two main pathways. The push-pull experiments show breakthrough curve tailing decreases as the volume of investigation increases, with a power law slope ranging from -3 to -2.3 from the smallest to the largest volume. The multipath model developed by Becker and Shapiro (2003) is used here to evaluate the hypothesis of the independence of flow pathways. The multipath model is found to explain the convergent data, when increasing local dispersivity and reducing the number of pathways with distance which suggest a transition from non-Fickian to Fickian transport at fracture scale. However, this model predicts an increase of tailing with push-pull distance, while the experiments show the opposite trend. This inconsistency may suggest the activation of cross channel mass transfer at larger volume of investigation, which leads to non-reversible heterogeneous advection with scale. This transition from independent channels to connected channels when the volume of investigation increases suggest that both convergent and push-pull breakthrough curves can inform the existence of characteristic length scales.
Collapse
Affiliation(s)
- N Guihéneuf
- BRGM, D3E, NRE, Indo-French Center for Groundwater Research, Uppal Road, 500007 Hyderabad, India; OSUR, Géosciences Rennes, UMR6118 CNRS - Université de Rennes 1, Campus de Beaulieu, 35042 Rennes Cedex, France.
| | - O Bour
- OSUR, Géosciences Rennes, UMR6118 CNRS - Université de Rennes 1, Campus de Beaulieu, 35042 Rennes Cedex, France
| | - A Boisson
- BRGM, D3E, NRE, Indo-French Center for Groundwater Research, Uppal Road, 500007 Hyderabad, India
| | - T Le Borgne
- OSUR, Géosciences Rennes, UMR6118 CNRS - Université de Rennes 1, Campus de Beaulieu, 35042 Rennes Cedex, France
| | - M W Becker
- Department of Geological Sciences, California State University Long Beach, Long Beach, California, 90840, United States
| | - B Nigon
- BRGM, D3E, NRE, Indo-French Center for Groundwater Research, Uppal Road, 500007 Hyderabad, India
| | - M Wajiduddin
- Indo-French Center for Groundwater Research, Uppal Road, 500007 Hyderabad, India
| | - S Ahmed
- National Geophysical Research Institute, Indo-French Center for Groundwater Research, Uppal Road, 500007 Hyderabad, India
| | - J-C Maréchal
- BRGM, D3E, NRE, 1039 rue de Pinville, 34000 Montpellier, France
| |
Collapse
|
14
|
Willard-Gallo K, Solinas C, Marcoux D, t'Kint de Roodenbeke D, Garaud S, Van den Eynden G, de Wind A, Boisson A, Larsimont D, Piccart M. Abstract P2-04-04: BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-04-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The remarkable responses observed in metastatic cancer patients treated with immunotherapies, including inhibitors directed to the PD-1 and PD-L1 checkpoint molecules, makes it a priority to identify critical variations in pro- and anti-tumor immune responses in breast cancer (BC). In patients with triple negative (TN) BC, an increased presence of tumor infiltrating lymphocytes (TIL) and tertiary lymphoid structures (TLS) have been associated with good clinical outcomes. However, the frequency of specific lymphocyte subpopulations, PD-1 and/or PD-L1 expression and their prognostic significance remains an open question. Our recent work found that PD-1 and PD-L1 expression are specifically associated with higher TIL densities and an increased number of TLS in BC. We further demonstrated that TIL density, TLS and PD-L1 expression were correlated with more aggressive breast tumor characteristics, including higher proliferation and hormone receptor negativity. In this project, we examined the prevalence of TIL, TLS, PD-1 and PD-L1 expression in TNBC and further compared these immune parameters between TNBC patients harboring BRCA1 or BRCA2 germline gene mutations with those carrying the wild-type (wt) genes.
A total of 1402 BC patients whose blood was genetically tested for germline BRCA1 and BRCA2 mutations were examined for inclusion in this study. Ninety-eight chemotherapy-naïve patients with primary invasive ER–, PR– and HER2– BC and demonstrated germline BRCA1 or BRCA2 wt or mutated-gene status were included in this study. Ninety-four tumors were determined to be suitable for evaluating immune cell infiltration (51 BRCA wt and 43 BRCA-mutated). FFPE tumor tissue from the surgical specimens was analyzed by immunohistochemistry (IHC) staining of full-face tissue sections. IHC was performed as a dual label using CD3 plus CD20 for T and B cells, CD4 plus CD8 for the major T cell subpopulations and PD-1 plus PD-L1 for individual or paired expression of these receptors. The stained slides were independently scored by two experienced pathologists for TIL, TIL subpopulations, TLS and checkpoint molecule expression.
These analyses revealed that 87% of our TNBC cohort was TIL-positive (≥10% TIL) with 35% classified as lymphocyte predominant BC (LPBC; ≥50% TIL). T cells were the principal component of the lymphocytic infiltrate with no significant differences between the BRCA wt and BRCA-mutated groups detected in total T cells (CD3+), helper T cells (CD4+), cytotoxic T cells (CD8+) or B cells (CD20+). TLS were identified in 73% of tumors with again no significant differences between the BRCA groups. Examination of checkpoint molecule expression identified 33% tumors as PD-1 positive and 40% as PD-L1 positive. PD-1 expression was correlated with PD-L1 expression and both with TIL positivity and the level of immune infiltration but not BRCA mutational status.
Overall, our analyses revealed that BRCA wt and BRCA-mutated TNBC are remarkably similar in terms of TIL heterogeneity, a TLS presence and checkpoint molecule expression. These data suggest that BRCA gene mutations are not immunogenic nor do they directly drive immune infiltration in TNBC.
Citation Format: Willard-Gallo K, Solinas C, Marcoux D, t'Kint de Roodenbeke D, Garaud S, Van den Eynden G, de Wind A, Boisson A, Larsimont D, Piccart M. BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-04-04.
Collapse
Affiliation(s)
- K Willard-Gallo
- Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; GZA Ziekenhuizen, Wilrijk, Belgium
| | - C Solinas
- Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; GZA Ziekenhuizen, Wilrijk, Belgium
| | - D Marcoux
- Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; GZA Ziekenhuizen, Wilrijk, Belgium
| | - D t'Kint de Roodenbeke
- Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; GZA Ziekenhuizen, Wilrijk, Belgium
| | - S Garaud
- Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; GZA Ziekenhuizen, Wilrijk, Belgium
| | - G Van den Eynden
- Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; GZA Ziekenhuizen, Wilrijk, Belgium
| | - A de Wind
- Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; GZA Ziekenhuizen, Wilrijk, Belgium
| | - A Boisson
- Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; GZA Ziekenhuizen, Wilrijk, Belgium
| | - D Larsimont
- Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; GZA Ziekenhuizen, Wilrijk, Belgium
| | - M Piccart
- Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; GZA Ziekenhuizen, Wilrijk, Belgium
| |
Collapse
|
15
|
Solinas C, Boisson A, Brown D, de Wind R, van den Eynden G, Garaud S, Buisseret L, Naveaux C, Sotiriou C, Larsimont D, Piccart M, Willard-Gallo K. Tumor infiltrating lymphocytes and tertiary lymphoid structures in paired primary tumors and metastases from breast cancer patients. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw393.07] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
16
|
Solinas C, Buisseret L, Garaud S, Boisson A, Naveaux C, de Wind R, Van den Eynden G, Brown D, Larsimont D, Sotiriou C, Willard-Gallo K. PDL1 and PD1 expression by tumor infiltrating lymphocytes in primary breast cancer. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv336.04] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Solinas C, Buisseret L, Garaud S, Boisson A, Naveaux C, De Silva P, Migliori E, de Wind R, Larsimont D, Willard-Gallo K. Evaluation of PDL1 expression in breast cancer by immunohistochemistry. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv118.04] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
Migliori E, Gu-Trantien C, Garaud S, Buisseret L, Duvillier H, Lodewyckx JN, Van Schoonwinkel L, Boisson A, Willard-Gallo K. CXCL13 and tertiary lymphoid structures formation in the anti-breast cancer immune response. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv118.03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
De Silva P, Garaud S, Migliori E, Solinas C, Boisson A, Naveaux C, Pecenko S, de Wind R, Larsimont D, Willard-Gallo K. Expression of transcription factor FOXP1 in the immune response to breast cancer. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv118.05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
20
|
Boisson A, de Anna P, Bour O, Le Borgne T, Labasque T, Aquilina L. Reaction chain modeling of denitrification reactions during a push-pull test. J Contam Hydrol 2013; 148:1-11. [PMID: 23500936 DOI: 10.1016/j.jconhyd.2013.02.006] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/03/2012] [Revised: 01/29/2013] [Accepted: 02/08/2013] [Indexed: 05/05/2023]
Abstract
Field quantitative estimation of reaction kinetics is required to enhance our understanding of biogeochemical reactions in aquifers. We extended the analytical solution developed by Haggerty et al. (1998) to model an entire 1st order reaction chain and estimate the kinetic parameters for each reaction step of the denitrification process. We then assessed the ability of this reaction chain to model biogeochemical reactions by comparing it with experimental results from a push-pull test in a fractured crystalline aquifer (Ploemeur, French Brittany). Nitrates were used as the reactive tracer, since denitrification involves the sequential reduction of nitrates to nitrogen gas through a chain reaction (NO3(-)→NO2(-)→NO→N2O→N2) under anaerobic conditions. The kinetics of nitrate consumption and by-product formation (NO2(-), N2O) during autotrophic denitrification were quantified by using a reactive tracer (NO3(-)) and a non-reactive tracer (Br(-)). The formation of reaction by-products (NO2(-), N2O, N2) has not been previously considered using a reaction chain approach. Comparison of Br(-) and NO3(-) breakthrough curves showed that 10% of the injected NO3(-) molar mass was transformed during the 12 h experiment (2% into NO2(-), 1% into N2O and the rest into N2 and NO). Similar results, but with slower kinetics, were obtained from laboratory experiments in reactors. The good agreement between the model and the field data shows that the complete denitrification process can be efficiently modeled as a sequence of first order reactions. The 1st order kinetics coefficients obtained through modeling were as follows: k1=0.023 h(-1), k2=0.59 h(-1), k3=16 h(-1), and k4=5.5 h(-1). A next step will be to assess the variability of field reactivity using the methodology developed for modeling push-pull tracer tests.
Collapse
Affiliation(s)
- A Boisson
- Géosciences Rennes-OSUR, UMR CNRS 6118, University of Rennes 1, France.
| | | | | | | | | | | |
Collapse
|
21
|
Gout E, Boisson A, Aubert S, Douce R, Bligny R. Origin of the cytoplasmic pH changes during anaerobic stress in higher plant cells. Carbon-13 and phosphorous-31 nuclear magnetic resonance studies. Plant Physiol 2001; 125:912-25. [PMID: 11161048 PMCID: PMC64892 DOI: 10.1104/pp.125.2.912] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/13/2000] [Revised: 09/06/2000] [Accepted: 11/03/2000] [Indexed: 05/18/2023]
Abstract
We tested the contribution of nucleoside triphosphate (NTP) hydrolysis, ethanol, and organic acid syntheses, and H(+)-pump ATPases activity in the acidosis of anoxic sycamore (Acer pseudoplatanus) plant cells. Culture cells were chosen to alter NTP pools and fermentation with specific nutrient media (phosphate [Pi]-deprived and adenine- or glycerol-supplied). In vivo (31)P- and (13)C-nuclear magnetic resonance (NMR) spectroscopy was utilized to noninvasively measure intracellular pHs, Pi, phosphomonoesters, nucleotides, lactate, and ethanol. Following the onset of anoxia, cytoplasmic (cyt) pH (7.5) decreased to 6.8 within 4 to 5 min, whereas vacuolar pH (5.7) and external pH (6.5) remained stable. The NTP pool simultaneously decreased from 210 to <20 nmol g(-1) cell wet weight, whereas nuceloside diphosphate, nucleoside monophosphate, and cyt pH increased correspondingly. The initial cytoplasmic acidification was at a minimum in Pi-deprived cells containing little NTP, and at a maximum in adenine-incubated cells showing the highest NTP concentration. Our data show that the release of H(+) ions accompanying the Pi-liberating hydrolysis of NTP was the principal cause of the initial cyt pH drop and that this cytoplasmic acidosis was not overcome by H(+) extrusion. After 15 min of anoxia, a partial cyt-pH recovery observed in cells supplied with Glc, but not with glycerol, was attributed to the H(+)-consuming ATP synthesis accompanying ethanolic fermentation. Following re-oxygenation, the cyt pH recovered its initial value (7.5) within 2 to 3 min, whereas external pH decreased abruptly. We suggest that the H(+)-pumping ATPase located in the plasma membrane was blocked in anoxia and quickly reactivated after re-oxygenation.
Collapse
Affiliation(s)
- E Gout
- Laboratoire de Physiologie Cellulaire Végétale, Unité Mixte de Recherche 5019, Département de Biologie Moléculaire et Structurale, CEA-Grenoble, Grenoble cedex 9, France
| | | | | | | | | |
Collapse
|
22
|
Deyrieux F, Boisson A, Castelnovo P. [Left ventricular obstructive myocardiopathy. Phonomecanographic diagnosis of the late form with amyl nitrite]. Nouv Presse Med 1972; 1:1703-4. [PMID: 5064944] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|
23
|
Deyrieux F, Boisson A, Castelnovo P. [Phono-mechanographic diagnosis of late forms of obstructive myocardiopathy of the left ventricle]. J Med Lyon 1972; 53:845-57. [PMID: 4672387] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
24
|
Deyrieux F, Blum J, Tartulier M, Boisson A, Tourniaire A. [The left apical cardiogram in mitral insufficiency. Critical study]. Arch Mal Coeur Vaiss 1967; 60:1382-91. [PMID: 4965396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|